Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X Cybersecurity (BUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global X Cybersecurity — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.65 (market cap $4.49B), while Global X Cybersecurity trades at $39.46. The key difference: Global X Cybersecurity is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | BUG | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $40.67 |
52-Week Low | $20.06 | $23.30 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BUG trades at $40.67, up 3.41% today, with a bullish technical trend supported by moving averages but overbought RSI levels. The cybersecurity ETF benefits from sector tailwinds as global spending exceeds $300 billion in 2026 (24/7 Wall Street, 2026-07-03), though AI disruption poses challenges. Key support lies at $39, with resistance at $41.
Outlook is mixed: strong sector growth supports upside, but premium valuations and AI-driven competitive threats present risks. Investors should weigh robust cybersecurity demand against potential earnings compression from rapid technological shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →
